Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 • 10,779 citations

The biology of VEGF and its receptors

2003 • 9,272 citations

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

2006 • 5,595 citations

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 • 5,383 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2003 • 2,874 citations

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

2003 • 2,522 citations

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

2005 • 2,102 citations

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

2004 • 1,894 citations

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

2004 • 1,723 citations

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

2005 • 1,517 citations

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

2002 • 784 citations

Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer

2005 • 673 citations

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

2002 • 554 citations

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

2005 • 538 citations

Epidermal growth factor receptor inhibition strategies in oncology

2004 • 413 citations

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

2003 • 318 citations

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

2005 • 309 citations

Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors

2002 • 308 citations

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

2004 • 239 citations

Malignant Pleural Effusions

1985 • 238 citations

RET and neuroendocrine tumors

2003 • 196 citations

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer

2005 • 196 citations

Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.

1999 • 193 citations

ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

2005 • 170 citations

Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer Cells

2000 • 154 citations

Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.

2000 • 153 citations

Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma

2006 • 141 citations

A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100

2006 • 137 citations

ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy

2004 • 134 citations

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

2006 • 129 citations

Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions

1999 • 125 citations

Small In-Frame Deletion in the Epidermal Growth Factor Receptor as a Target for ZD6474

2004 • 120 citations

Vascular Endothelial Growth Factor in Pleural Fluid

1999 • 116 citations

ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial

2006 • 110 citations

Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial

2006 • 101 citations

Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer

2006 • 91 citations

The Cardiotoxic Potential of the 5-HT3 Receptor Antagonist Antiemetics: Is There Cause for Concern?

2002 • 76 citations

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

2006 • 74 citations

A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results

2006 • 73 citations

A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145

2006 • 70 citations

Malignant pleural effusions

2002 • 61 citations

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)‐sensitive and resistant xenograft models

2004 • 60 citations

A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer

2006 • 48 citations

Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1^st-line treatment in patients with NSCLC

2005 • 43 citations

Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor

2005 • 40 citations

ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study

2004 • 20 citations

Emerging Antiangiogenic Agents in Lung Cancer

2006 • 20 citations

P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study

2005 • 15 citations

ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer

2004 • 13 citations

A randomized double-blind phase IIa dose-finding study of ZD6474 in Japanese patients with NSCLC

2006 • 9 citations

ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study

2004 • 7 citations

Biology and novel therapeutics for neuroendocrine tumors of the lung.

2005 • 5 citations

The effect of food on and the intra-subject variability of the pharmacokinetics of ZD6474, a novel antiangiogenic agent, in healthy subjects

2004 • 5 citations

Combined blockade of VEGFR and EGFR with ZD6474 enhances the antitumor and antivascular effects of radiation therapy in an orthotopic mouse model of human lung cancer

2005 • 2 citations